OBJECTIVES: It is now widely accepted that ADHD is a frequent chronic condition with a lifelong perspective. Adult ADHD is a reliable and valid diagnosis. The disorder and the co-morbid conditions can place a severe burden on the patients, their families and their partners, requiring adequate treatment. METHODS: A systematic literature search was conducted to review the available pharmacological treatment options for adults with ADHD in European countries. RESULTS: Supported by meta-analyses, stimulant medication is the first-line pharmacological therapy for adult ADHD. However, from a European perspective the pharmacological treatment options are very limited and only a minority of adults with ADHD in European countries receives adequate treatment. CONCLUSIONS: With reference to the epidemiological data, it seems very likely that the number of people with ADHD in Europe seeking multimodal treatment including pharmacotherapy, psychotherapy, coaching or other therapeutic services will increase profoundly during the coming years.
OBJECTIVES: It is now widely accepted that ADHD is a frequent chronic condition with a lifelong perspective. Adult ADHD is a reliable and valid diagnosis. The disorder and the co-morbid conditions can place a severe burden on the patients, their families and their partners, requiring adequate treatment. METHODS: A systematic literature search was conducted to review the available pharmacological treatment options for adults with ADHD in European countries. RESULTS: Supported by meta-analyses, stimulant medication is the first-line pharmacological therapy for adult ADHD. However, from a European perspective the pharmacological treatment options are very limited and only a minority of adults with ADHD in European countries receives adequate treatment. CONCLUSIONS: With reference to the epidemiological data, it seems very likely that the number of people with ADHD in Europe seeking multimodal treatment including pharmacotherapy, psychotherapy, coaching or other therapeutic services will increase profoundly during the coming years.
Authors: Thomas Vanicek; Alexandra Kutzelnigg; Cecile Philippe; Helen L Sigurdardottir; Gregory M James; Andreas Hahn; Georg S Kranz; Anna Höflich; Alexander Kautzky; Tatjana Traub-Weidinger; Marcus Hacker; Wolfgang Wadsak; Markus Mitterhauser; Siegfried Kasper; Rupert Lanzenberger Journal: Hum Brain Mapp Date: 2016-10-22 Impact factor: 5.038
Authors: Eric Q Wu; Paul Hodgkins; Rym Ben-Hamadi; Juliana Setyawan; Jipan Xie; Vanja Sikirica; Ella X Du; Sherry Y Yan; M Haim Erder Journal: CNS Drugs Date: 2012-07-01 Impact factor: 5.749